Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Another Setback For Lexicon, But Not In Diabetes

Lexicon Pharmaceuticals (NASDAQ:LXRX) continues to see its pipeline winnowed down by clinical trial failures. A prospective drug for rheumatoid arthritis basically went away last year, and it was just about two months ago that the company announced that LX 1032 (telotristat etiprate) had failed to show significant efficacy in a Phase II study in ulcerative colitis. Now there's another piece of bad news to digest, as the company announced Tuesday morning that its Phase II study of LX 1033 in IBS-D (diarrhea-prominent irritable bowel syndrome) failed to meet its primary endpoint.

Lexicon may, or may not, go forward with another study of LX 1033 on the basis of post-hoc analysis that appears to suggest some efficacy. Either way,...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details